JP2003523324A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2003523324A5 JP2003523324A5 JP2001543093A JP2001543093A JP2003523324A5 JP 2003523324 A5 JP2003523324 A5 JP 2003523324A5 JP 2001543093 A JP2001543093 A JP 2001543093A JP 2001543093 A JP2001543093 A JP 2001543093A JP 2003523324 A5 JP2003523324 A5 JP 2003523324A5
- Authority
- JP
- Japan
- Prior art keywords
- alkyl
- hydrogen
- receptor
- antagonists
- formula
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 125000000217 alkyl group Chemical group 0.000 description 74
- 239000001257 hydrogen Substances 0.000 description 40
- 229910052739 hydrogen Inorganic materials 0.000 description 40
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 28
- 229940044551 receptor antagonist Drugs 0.000 description 18
- 239000002464 receptor antagonist Substances 0.000 description 18
- 239000000018 receptor agonist Substances 0.000 description 14
- 229940044601 receptor agonist Drugs 0.000 description 14
- 150000001875 compounds Chemical class 0.000 description 13
- 150000003839 salts Chemical class 0.000 description 13
- QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 description 12
- 125000003118 aryl group Chemical group 0.000 description 10
- 229910052736 halogen Inorganic materials 0.000 description 10
- 150000002367 halogens Chemical class 0.000 description 10
- 150000002431 hydrogen Chemical class 0.000 description 10
- 125000004356 hydroxy functional group Chemical group O* 0.000 description 10
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 10
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 8
- 239000003795 chemical substances by application Substances 0.000 description 8
- 239000003814 drug Substances 0.000 description 8
- -1 piperidino, pyrazinyl Chemical group 0.000 description 8
- 239000008141 laxative Substances 0.000 description 7
- 229940126409 proton pump inhibitor Drugs 0.000 description 7
- IKBKZGMPCYNSLU-RGVLZGJSSA-N tegaserod Chemical compound C1=C(OC)C=C2C(/C=N/NC(=N)NCCCCC)=CNC2=C1 IKBKZGMPCYNSLU-RGVLZGJSSA-N 0.000 description 7
- 229960002876 tegaserod Drugs 0.000 description 7
- 125000006705 (C5-C7) cycloalkyl group Chemical group 0.000 description 6
- 125000003236 benzoyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C(*)=O 0.000 description 6
- 125000000623 heterocyclic group Chemical group 0.000 description 6
- 150000003254 radicals Chemical class 0.000 description 6
- 230000005176 gastrointestinal motility Effects 0.000 description 5
- 229940125722 laxative agent Drugs 0.000 description 5
- 239000000902 placebo Substances 0.000 description 5
- 229940068196 placebo Drugs 0.000 description 5
- 125000002030 1,2-phenylene group Chemical group [H]C1=C([H])C([*:1])=C([*:2])C([H])=C1[H] 0.000 description 4
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 4
- 125000005073 adamantyl group Chemical group C12(CC3CC(CC(C1)C3)C2)* 0.000 description 4
- 125000003545 alkoxy group Chemical group 0.000 description 4
- 125000004453 alkoxycarbonyl group Chemical group 0.000 description 4
- 125000004448 alkyl carbonyl group Chemical group 0.000 description 4
- 239000002249 anxiolytic agent Substances 0.000 description 4
- 125000004104 aryloxy group Chemical group 0.000 description 4
- 229940000425 combination drug Drugs 0.000 description 4
- 229940079593 drug Drugs 0.000 description 4
- 230000035945 sensitivity Effects 0.000 description 4
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 3
- 241000282472 Canis lupus familiaris Species 0.000 description 3
- 102000009493 Neurokinin receptors Human genes 0.000 description 3
- 108050000302 Neurokinin receptors Proteins 0.000 description 3
- 102000003840 Opioid Receptors Human genes 0.000 description 3
- 108090000137 Opioid Receptors Proteins 0.000 description 3
- 229940127504 Somatostatin Receptor Agonists Drugs 0.000 description 3
- 230000003187 abdominal effect Effects 0.000 description 3
- 230000003110 anti-inflammatory effect Effects 0.000 description 3
- 229940126523 co-drug Drugs 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 239000003149 muscarinic antagonist Substances 0.000 description 3
- 230000003204 osmotic effect Effects 0.000 description 3
- MEZLKOACVSPNER-GFCCVEGCSA-N selegiline Chemical compound C#CCN(C)[C@H](C)CC1=CC=CC=C1 MEZLKOACVSPNER-GFCCVEGCSA-N 0.000 description 3
- 239000003369 serotonin 5-HT3 receptor antagonist Substances 0.000 description 3
- 125000004890 (C1-C6) alkylamino group Chemical group 0.000 description 2
- RTHCYVBBDHJXIQ-MRXNPFEDSA-N (R)-fluoxetine Chemical compound O([C@H](CCNC)C=1C=CC=CC=1)C1=CC=C(C(F)(F)F)C=C1 RTHCYVBBDHJXIQ-MRXNPFEDSA-N 0.000 description 2
- 239000003185 4 aminobutyric acid B receptor stimulating agent Substances 0.000 description 2
- PIGFYZPCRLYGLF-UHFFFAOYSA-N Aluminum nitride Chemical compound [Al]#N PIGFYZPCRLYGLF-UHFFFAOYSA-N 0.000 description 2
- QPADXYFHJYCILH-UHFFFAOYSA-N CN/C(/N)=N/N=C Chemical compound CN/C(/N)=N/N=C QPADXYFHJYCILH-UHFFFAOYSA-N 0.000 description 2
- 102000014468 Calcitonin Gene-Related Peptide Receptors Human genes 0.000 description 2
- 108010078311 Calcitonin Gene-Related Peptide Receptors Proteins 0.000 description 2
- 102000004859 Cholecystokinin Receptors Human genes 0.000 description 2
- 108090001085 Cholecystokinin Receptors Proteins 0.000 description 2
- NTYJJOPFIAHURM-UHFFFAOYSA-N Histamine Chemical compound NCCC1=CN=CN1 NTYJJOPFIAHURM-UHFFFAOYSA-N 0.000 description 2
- 102000057413 Motilin receptors Human genes 0.000 description 2
- 108700040483 Motilin receptors Proteins 0.000 description 2
- 229940123445 Tricyclic antidepressant Drugs 0.000 description 2
- 230000002745 absorbent Effects 0.000 description 2
- 239000002250 absorbent Substances 0.000 description 2
- 125000003806 alkyl carbonyl amino group Chemical group 0.000 description 2
- UPNUIXSCZBYVBB-JVFUWBCBSA-N alvimopan Chemical compound C([C@@H](CN1C[C@@H]([C@](CC1)(C)C=1C=C(O)C=CC=1)C)C(=O)NCC(O)=O)C1=CC=CC=C1 UPNUIXSCZBYVBB-JVFUWBCBSA-N 0.000 description 2
- 229940069428 antacid Drugs 0.000 description 2
- 239000003159 antacid agent Substances 0.000 description 2
- 230000003474 anti-emetic effect Effects 0.000 description 2
- 230000002921 anti-spasmodic effect Effects 0.000 description 2
- 239000002111 antiemetic agent Substances 0.000 description 2
- 230000000949 anxiolytic effect Effects 0.000 description 2
- 229940005530 anxiolytics Drugs 0.000 description 2
- 125000003785 benzimidazolyl group Chemical group N1=C(NC2=C1C=CC=C2)* 0.000 description 2
- 229910052797 bismuth Inorganic materials 0.000 description 2
- JCXGWMGPZLAOME-UHFFFAOYSA-N bismuth atom Chemical compound [Bi] JCXGWMGPZLAOME-UHFFFAOYSA-N 0.000 description 2
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 2
- 239000000812 cholinergic antagonist Substances 0.000 description 2
- 230000004600 colonic motility Effects 0.000 description 2
- 125000004093 cyano group Chemical group *C#N 0.000 description 2
- VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical compound NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 description 2
- 150000002148 esters Chemical class 0.000 description 2
- 239000000835 fiber Substances 0.000 description 2
- 229960002464 fluoxetine Drugs 0.000 description 2
- 239000007789 gas Substances 0.000 description 2
- 208000021302 gastroesophageal reflux disease Diseases 0.000 description 2
- 239000003485 histamine H2 receptor antagonist Substances 0.000 description 2
- 210000003630 histaminocyte Anatomy 0.000 description 2
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 2
- 229960000930 hydroxyzine Drugs 0.000 description 2
- ZQDWXGKKHFNSQK-UHFFFAOYSA-N hydroxyzine Chemical compound C1CN(CCOCCO)CCN1C(C=1C=CC(Cl)=CC=1)C1=CC=CC=C1 ZQDWXGKKHFNSQK-UHFFFAOYSA-N 0.000 description 2
- 125000002883 imidazolyl group Chemical group 0.000 description 2
- 239000002085 irritant Substances 0.000 description 2
- 231100000021 irritant Toxicity 0.000 description 2
- 230000002475 laxative effect Effects 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 239000000236 nitric oxide synthase inhibitor Substances 0.000 description 2
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 description 2
- 229910052757 nitrogen Inorganic materials 0.000 description 2
- 125000004433 nitrogen atom Chemical group N* 0.000 description 2
- 239000004031 partial agonist Substances 0.000 description 2
- 229940043138 pentosan polysulfate Drugs 0.000 description 2
- 239000008194 pharmaceutical composition Substances 0.000 description 2
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 2
- 239000000612 proton pump inhibitor Substances 0.000 description 2
- 229960003863 prucalopride Drugs 0.000 description 2
- ZPMNHBXQOOVQJL-UHFFFAOYSA-N prucalopride Chemical compound C1CN(CCCOC)CCC1NC(=O)C1=CC(Cl)=C(N)C2=C1OCC2 ZPMNHBXQOOVQJL-UHFFFAOYSA-N 0.000 description 2
- 125000004076 pyridyl group Chemical group 0.000 description 2
- 125000000719 pyrrolidinyl group Chemical group 0.000 description 2
- 125000004929 pyrrolidonyl group Chemical group N1(C(CCC1)=O)* 0.000 description 2
- 229940075993 receptor modulator Drugs 0.000 description 2
- CSYSULGPHGCBQD-UHFFFAOYSA-N s-ethylisothiouronium diethylphosphate Chemical compound CCSC(N)=N.CCOP(O)(=O)OCC CSYSULGPHGCBQD-UHFFFAOYSA-N 0.000 description 2
- 238000012216 screening Methods 0.000 description 2
- 230000028327 secretion Effects 0.000 description 2
- 239000003381 stabilizer Substances 0.000 description 2
- 239000013589 supplement Substances 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 239000003029 tricyclic antidepressant agent Substances 0.000 description 2
- 125000000026 trimethylsilyl group Chemical group [H]C([H])([H])[Si]([*])(C([H])([H])[H])C([H])([H])[H] 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- IKBKZGMPCYNSLU-UHFFFAOYSA-N 1-[(5-methoxy-1H-indol-3-yl)methylideneamino]-2-pentylguanidine Chemical compound C1=C(OC)C=C2C(C=NNC(=N)NCCCCC)=CNC2=C1 IKBKZGMPCYNSLU-UHFFFAOYSA-N 0.000 description 1
- FWWOWPGPERBCNJ-UHFFFAOYSA-N 2-hydroxy-4-(2-hydroxyethoxy)-4-oxobutanoic acid Chemical group OCCOC(=O)CC(O)C(O)=O FWWOWPGPERBCNJ-UHFFFAOYSA-N 0.000 description 1
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical class [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 1
- 229940118499 Corticotropin releasing factor receptor agonist Drugs 0.000 description 1
- 229940122402 Corticotropin releasing factor receptor antagonist Drugs 0.000 description 1
- 108010056643 Corticotropin-Releasing Hormone Receptors Proteins 0.000 description 1
- 102100038018 Corticotropin-releasing factor receptor 1 Human genes 0.000 description 1
- 206010063655 Erosive oesophagitis Diseases 0.000 description 1
- MKXZASYAUGDDCJ-SZMVWBNQSA-N LSM-2525 Chemical compound C1CCC[C@H]2[C@@]3([H])N(C)CC[C@]21C1=CC(OC)=CC=C1C3 MKXZASYAUGDDCJ-SZMVWBNQSA-N 0.000 description 1
- 102000014415 Muscarinic acetylcholine receptor Human genes 0.000 description 1
- 108050003473 Muscarinic acetylcholine receptor Proteins 0.000 description 1
- 229940121948 Muscarinic receptor antagonist Drugs 0.000 description 1
- 230000008485 antagonism Effects 0.000 description 1
- 239000005557 antagonist Substances 0.000 description 1
- 230000001458 anti-acid effect Effects 0.000 description 1
- 229940125681 anticonvulsant agent Drugs 0.000 description 1
- 239000001961 anticonvulsive agent Substances 0.000 description 1
- 125000003310 benzodiazepinyl group Chemical class N1N=C(C=CC2=C1C=CC=C2)* 0.000 description 1
- 239000003246 corticosteroid Substances 0.000 description 1
- 229960001985 dextromethorphan Drugs 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 229960003638 dopamine Drugs 0.000 description 1
- 239000000442 dopamine 2 receptor blocking agent Substances 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 201000006549 dyspepsia Diseases 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- 235000012631 food intake Nutrition 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 208000024798 heartburn Diseases 0.000 description 1
- 229960001340 histamine Drugs 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 230000002427 irreversible effect Effects 0.000 description 1
- 229940099076 maalox Drugs 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- 229960004503 metoclopramide Drugs 0.000 description 1
- TTWJBBZEZQICBI-UHFFFAOYSA-N metoclopramide Chemical compound CCN(CC)CCNC(=O)C1=CC(Cl)=C(N)C=C1OC TTWJBBZEZQICBI-UHFFFAOYSA-N 0.000 description 1
- 230000003551 muscarinic effect Effects 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 229940002612 prodrug Drugs 0.000 description 1
- 239000000651 prodrug Substances 0.000 description 1
- 239000002325 prokinetic agent Substances 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 229940127558 rescue medication Drugs 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 230000003248 secreting effect Effects 0.000 description 1
- 229940124834 selective serotonin reuptake inhibitor Drugs 0.000 description 1
- 239000012896 selective serotonin reuptake inhibitor Substances 0.000 description 1
- 229960003946 selegiline Drugs 0.000 description 1
- 239000003523 serotonin 4 antagonist Substances 0.000 description 1
- 239000008143 stimulant laxative Substances 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000002966 varnish Substances 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US45838899A | 1999-12-10 | 1999-12-10 | |
| US09/458,388 | 1999-12-10 | ||
| PCT/EP2000/012420 WO2001041748A2 (en) | 1999-12-10 | 2000-12-08 | Pharmaceutical combinations and their use in treating gastrointestinal disorders |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2003523324A JP2003523324A (ja) | 2003-08-05 |
| JP2003523324A5 true JP2003523324A5 (https=) | 2008-01-24 |
Family
ID=23820591
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2001543093A Pending JP2003523324A (ja) | 1999-12-10 | 2000-12-08 | 組合せ医薬および胃腸疾患の処置へのそれらの使用 |
Country Status (30)
| Country | Link |
|---|---|
| EP (3) | EP1286668B1 (https=) |
| JP (1) | JP2003523324A (https=) |
| KR (1) | KR100765579B1 (https=) |
| CN (2) | CN1875966A (https=) |
| AR (1) | AR026916A1 (https=) |
| AT (1) | ATE293971T1 (https=) |
| AU (2) | AU778869B2 (https=) |
| BR (1) | BR0016275A (https=) |
| CA (1) | CA2388959A1 (https=) |
| CO (1) | CO5261535A1 (https=) |
| CZ (1) | CZ300690B6 (https=) |
| DE (1) | DE60019814T2 (https=) |
| DK (1) | DK1286668T3 (https=) |
| ES (1) | ES2240229T3 (https=) |
| HU (1) | HUP0301122A3 (https=) |
| IL (2) | IL149496A0 (https=) |
| MX (1) | MXPA02005695A (https=) |
| MY (1) | MY133423A (https=) |
| NO (1) | NO20022680L (https=) |
| NZ (2) | NZ531489A (https=) |
| PE (1) | PE20011030A1 (https=) |
| PL (1) | PL202201B1 (https=) |
| PT (1) | PT1286668E (https=) |
| RU (1) | RU2264215C2 (https=) |
| SG (1) | SG152025A1 (https=) |
| SK (1) | SK8062002A3 (https=) |
| TR (1) | TR200402293T2 (https=) |
| TW (1) | TWI263496B (https=) |
| WO (1) | WO2001041748A2 (https=) |
| ZA (1) | ZA200204493B (https=) |
Families Citing this family (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2001261606A1 (en) * | 2000-05-18 | 2001-11-26 | Glaxo Group Limited | Method for treating functional dyspepsia |
| GB0209481D0 (en) * | 2002-04-24 | 2002-06-05 | Novartis Ag | Organic compounds |
| NZ541009A (en) | 2003-01-13 | 2007-09-28 | Dynogen Pharmaceuticals Inc | Method of treating nausea, vomiting, retching or any combination thereof |
| GB0307440D0 (en) * | 2003-03-31 | 2003-05-07 | Novartis Ag | Organic compounds |
| JP2006528231A (ja) * | 2003-05-27 | 2006-12-14 | アルタナ ファルマ アクチエンゲゼルシャフト | プロトンポンプ阻害剤と胃腸運動性を変更する化合物との医薬品組合せ物 |
| US20050090554A1 (en) * | 2003-09-12 | 2005-04-28 | John Devane | Treatment of gastroparesis and nonulcer dyspepsia with GABAB agonists |
| US7820690B2 (en) | 2004-03-19 | 2010-10-26 | Solvay Pharmaceuticals Gmbh | Method of treating or inhibiting a non-digestive tract derived abdominal disorder associated with pain using a 5-HT, receptor antagonist |
| RU2007105346A (ru) * | 2004-07-14 | 2008-09-27 | Новартис АГ (CH) | Комбинация ингибиторов dpp-iv и соединений, модулирующих 5-нт3-и/или 5-нт4-рецепторы |
| MX2007009136A (es) * | 2005-01-31 | 2007-09-06 | Novartis Ag | Uso de agonista de 5-ht4 para tratar vacio gastrico retrasado que puede inducirse por un inhibidor de bomba de protones. |
| GB0506800D0 (en) * | 2005-04-04 | 2005-05-11 | Merck Sharp & Dohme | New uses |
| US8324192B2 (en) | 2005-11-12 | 2012-12-04 | The Regents Of The University Of California | Viscous budesonide for the treatment of inflammatory diseases of the gastrointestinal tract |
| US8497258B2 (en) | 2005-11-12 | 2013-07-30 | The Regents Of The University Of California | Viscous budesonide for the treatment of inflammatory diseases of the gastrointestinal tract |
| US8679545B2 (en) | 2005-11-12 | 2014-03-25 | The Regents Of The University Of California | Topical corticosteroids for the treatment of inflammatory diseases of the gastrointestinal tract |
| JP2009525269A (ja) | 2006-01-30 | 2009-07-09 | ユーロ−セルティーク エス．エイ． | カルシウムチャネルブロッカーとしての環状尿素化合物 |
| RU2008152196A (ru) * | 2006-06-15 | 2010-07-20 | Новартис АГ (CH) | Композиции, включающие тегасерод в отдельности или в комбинации с ингибитором протонного насоса, для лечения или профилактики повреждений желудочно-кишечного тракта |
| KR20090107088A (ko) | 2007-02-09 | 2009-10-12 | 트랜자임 파르마 인크 | 거대고리 그렐린 수용체 조절제 및 이의 사용 방법 |
| EP2214679B1 (en) | 2007-11-13 | 2019-03-27 | Meritage Pharma, Inc. | Corticosteroid compositions |
| US20090143343A1 (en) | 2007-11-13 | 2009-06-04 | Meritage Pharma, Inc. | Compositions for the treatment of inflammation of the gastrointestinal tract |
| GB201403775D0 (en) | 2014-03-04 | 2014-04-16 | Kymab Ltd | Antibodies, uses & methods |
| US9567399B1 (en) | 2016-06-20 | 2017-02-14 | Kymab Limited | Antibodies and immunocytokines |
| KR102379464B1 (ko) | 2016-06-20 | 2022-03-29 | 키맵 리미티드 | 항-pd-l1 항체 |
| WO2018029474A2 (en) | 2016-08-09 | 2018-02-15 | Kymab Limited | Anti-icos antibodies |
| KR20260030924A (ko) | 2016-08-09 | 2026-03-06 | 키맵 리미티드 | 항-icos 항체 |
| EP3534947A1 (en) | 2016-11-03 | 2019-09-11 | Kymab Limited | Antibodies, combinations comprising antibodies, biomarkers, uses & methods |
| GB201709808D0 (en) | 2017-06-20 | 2017-08-02 | Kymab Ltd | Antibodies |
| GB201721338D0 (en) | 2017-12-19 | 2018-01-31 | Kymab Ltd | Anti-icos Antibodies |
| EP3728314A1 (en) | 2017-12-19 | 2020-10-28 | Kymab Limited | Bispecific antibody for icos and pd-l1 |
| US20220396623A1 (en) | 2021-05-18 | 2022-12-15 | Kymab Limited | Uses of anti-icos antibodies |
| GB202107994D0 (en) | 2021-06-04 | 2021-07-21 | Kymab Ltd | Treatment of cancer |
| US20250340641A1 (en) | 2022-05-18 | 2025-11-06 | Kymab Limited | Uses of anti-icos antibodies |
| FR3144752A1 (fr) | 2023-01-10 | 2024-07-12 | Song Huang | Utilisation de polysulfate de pentosane pour le traitement de la toux seche |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5362756A (en) * | 1989-02-20 | 1994-11-08 | Riviere Pierre J M | Use of fedotozine in the treatment of functional states of intestinal obstructions |
| HUT64023A (en) * | 1991-03-22 | 1993-11-29 | Sandoz Ag | Process for producing aminoguanidine derivatives and pharmaceutical compositions comprising such compounds |
| EP0617620B1 (en) * | 1991-12-21 | 1998-09-09 | Smithkline Beecham Plc | Use of 5-ht4 - antagonists for the manufacture of a medicament for the treatment of urinary incontinence |
| GB9214184D0 (en) * | 1992-07-03 | 1992-08-12 | Smithkline Beecham Plc | Pharmaceuticals |
| DK0794184T3 (da) * | 1994-11-21 | 2001-07-30 | Dainippon Pharmaceutical Co | 6-Methoxy-1H-benzotriazol-5-carboxamidderivater, fremgangsmåde til fremstilling deraf og lægemidler indeholdende dem |
| US5919760A (en) * | 1996-04-12 | 1999-07-06 | Intensive Narcotic Detoxification Centers Of America, Llc | Method for treating acute and severe diarrhea |
| US6156771A (en) * | 1997-08-28 | 2000-12-05 | Rubin; Walter | Method for alleviation of lower gastrointestinal disorders in a human patient |
| GB9721139D0 (en) * | 1997-10-07 | 1997-12-03 | Glaxo Group Ltd | Medicaments |
-
2000
- 2000-11-20 TW TW089124545A patent/TWI263496B/zh not_active IP Right Cessation
- 2000-12-06 CO CO00093154A patent/CO5261535A1/es not_active Application Discontinuation
- 2000-12-07 PE PE2000001312A patent/PE20011030A1/es not_active Application Discontinuation
- 2000-12-07 AR ARP000106516A patent/AR026916A1/es unknown
- 2000-12-08 CN CNA2006100918377A patent/CN1875966A/zh active Pending
- 2000-12-08 MY MYPI20005769A patent/MY133423A/en unknown
- 2000-12-08 CZ CZ20021967A patent/CZ300690B6/cs not_active IP Right Cessation
- 2000-12-08 RU RU2002118316/15A patent/RU2264215C2/ru not_active IP Right Cessation
- 2000-12-08 EP EP00989967A patent/EP1286668B1/en not_active Expired - Lifetime
- 2000-12-08 EP EP04020247A patent/EP1488788A1/en not_active Withdrawn
- 2000-12-08 NZ NZ531489A patent/NZ531489A/en unknown
- 2000-12-08 PT PT00989967T patent/PT1286668E/pt unknown
- 2000-12-08 SK SK806-2002A patent/SK8062002A3/sk unknown
- 2000-12-08 CN CNB008168814A patent/CN1310644C/zh not_active Expired - Fee Related
- 2000-12-08 WO PCT/EP2000/012420 patent/WO2001041748A2/en not_active Ceased
- 2000-12-08 HU HU0301122A patent/HUP0301122A3/hu unknown
- 2000-12-08 NZ NZ566800A patent/NZ566800A/en unknown
- 2000-12-08 KR KR1020027007332A patent/KR100765579B1/ko not_active Expired - Fee Related
- 2000-12-08 TR TR2004/02293T patent/TR200402293T2/xx unknown
- 2000-12-08 IL IL14949600A patent/IL149496A0/xx unknown
- 2000-12-08 BR BR0016275-2A patent/BR0016275A/pt not_active Application Discontinuation
- 2000-12-08 DE DE60019814T patent/DE60019814T2/de not_active Expired - Lifetime
- 2000-12-08 PL PL355663A patent/PL202201B1/pl not_active IP Right Cessation
- 2000-12-08 ES ES00989967T patent/ES2240229T3/es not_active Expired - Lifetime
- 2000-12-08 JP JP2001543093A patent/JP2003523324A/ja active Pending
- 2000-12-08 AT AT00989967T patent/ATE293971T1/de not_active IP Right Cessation
- 2000-12-08 CA CA002388959A patent/CA2388959A1/en not_active Abandoned
- 2000-12-08 AU AU26728/01A patent/AU778869B2/en not_active Ceased
- 2000-12-08 MX MXPA02005695A patent/MXPA02005695A/es active IP Right Grant
- 2000-12-08 DK DK00989967T patent/DK1286668T3/da active
- 2000-12-08 SG SG200404415-2A patent/SG152025A1/en unknown
-
2002
- 2002-05-06 IL IL149496A patent/IL149496A/en not_active IP Right Cessation
- 2002-06-05 ZA ZA200204493A patent/ZA200204493B/xx unknown
- 2002-06-06 NO NO20022680A patent/NO20022680L/no not_active Application Discontinuation
-
2004
- 2004-08-26 EP EP07122308A patent/EP1913944A1/en not_active Withdrawn
-
2005
- 2005-02-22 AU AU2005200797A patent/AU2005200797B2/en not_active Ceased
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2003523324A5 (https=) | ||
| CN1236770C (zh) | 胃酸分泌抑制组合物 | |
| JP7258832B2 (ja) | 多発性硬化症を処置するためのｓ１ｐ受容体モジュレーター | |
| RU2264215C2 (ru) | Фармацевтические комбинации и их применение в лечении желудочно-кишечных заболеваний | |
| RU2586276C2 (ru) | Антагонист кислотного насоса для лечения заболеваний, связанных с патологическим нарушением моторики желудочно-кишечного тракта | |
| RU2435610C2 (ru) | Терапия для лечения заболевания | |
| JP5744947B2 (ja) | 流涎症の治療のためのアルファ−２受容体アゴニスト（クロニジン）と抗ムスカリン剤（オキシブチニン）との組み合わせ | |
| MX2008013779A (es) | Combinacion farmaceutica que comprende 3-(3-dimetilamino-1-etil-2- metil-propil)-fenol y paracetamol. | |
| CN1141937C (zh) | 含有曲马朵的药物组合物用于制备治疗偏头痛或类偏头痛的药物 | |
| BG63190B1 (bg) | Използване на оптически чист (+) норцисаприд за лечение на емезис и смущения на централната нервна система | |
| AU2012208863B2 (en) | Organic amine salts of azilsartan, preparation method and use thereof | |
| JP2005507387A5 (https=) | ||
| TWI419689B (zh) | 用於治療薩羅霍症（Ｓｉａｌｏｒｒｈｏｅａ）之醫藥組合物 | |
| CN104379138B (zh) | 阿坎酸制剂、其使用方法及包含阿坎酸制剂的组合 | |
| CN1543344A (zh) | 治疗尿失禁的芳基(或杂芳基)氮杂茂甲醇衍生物 | |
| MXPA02003452A (es) | Tratamiento de combinacion de esclerosis multiple (em), otras condiciones de desmielinacion y neuropatia periferica, especialmente neuropatias dolorosas y neuropatia diabetica. | |
| JP5935863B2 (ja) | 胃食道逆流症に対する薬剤 | |
| WO2004000855A1 (en) | Combination of an acid secretion inhibiting agent and a reflux inhibitor for the treatment of gerd | |
| JPWO2007007668A1 (ja) | 尿毒症改善のための治療剤および処置方法 | |
| HUE034676T2 (hu) | Gyógyszerkészítmény, amely tartalmaz (1R,4R)-6'fluor- N,N-dimetil-4-fenil-4',9'-dihidro-3'H-spiro[ciklohexán-1,1'-pirano'[3,4,B]indol]-4-amint és paracetamolt vagy propacetamolt | |
| JP4993998B2 (ja) | イブプロフェンを含有する医薬組成物 | |
| EP4543428A1 (en) | Methods of treating or preventing overactive bladder syndrome | |
| JPH07179346A (ja) | 胃腸治療剤 | |
| HK1035143B (en) | Pharmaceutical combinations containing tramadol for the production of a medicament for the treatment of migraine or migrainoid headaches | |
| WO2002042765A1 (fr) | Remedes destines a des troubles fonctionnels digestifs et procede de selection |